Skip to content

For Healthcare

Accurate, Actionable, and Affordable Diagnostic Solutions

To enable early detection of cancer and other diseases

Diagnostic solutions for cancer

0%
Gastric Cancer - Launched in May 2019 as GASTROClear
0%
Lung Cancer
0%
Breast Cancer
0%
Colorectal Cancer
0%
Ovarian Cancer
0%
Liver Cancer

GASTROClear

World's first blood test for early detection of gastric cancer

- Detects gastric cancer early for timely, life-saving treatment.

- Developed in collaboration with the Singapore Gastric Cancer Consortium, Diagnostics Development (DxD) Hub, National University Hospital (NUH), and Tan Tock Seng Hospital (TTSH).

- CE-marked in 2017 and approved by Singapore's Health Sciences Authority in May 2019 for in vitro diagnostic use as an adjunctive test in conjunction with endoscopy for gastric cancer detection.

- Available to patients at selected clinics in Singapore. Doctors can order GASTROClear through TTSH Molecular Diagnostic Laboratory (MDL) and Innovative Diagnostics.

Technical details

- GASTROClear detects 87.5% of stage 1 gastric cancers which have the highest patient survival rate.

- Clinical performance validated in a large-scale prospective study of over 5,000 subjects in Singapore.

- Manufactured in Singapore at our ISO 13485 certified facility.

Clinical utility

- In high prevalence countries such as Japan and Korea, GASTROClear can be an alternative non-invasive screening method for patients who refuse endoscopy, improving compliance with population screening.

- In intermediate prevalence countries such as Singapore, GASTROClear can be used as an adjunct test to assess gastric cancer risk prior to endoscopy for cost-effective population screening.

Diagnostic solutions for infectious, cardiovascular, and metabolic diseases

0%
COVID-19 - Launched in Feb 2020 as Fortitude Kit
0%
Heart Failure
0%
Pulmonary Hypertension
0%
Sepsis
0%
Insulin Resistance

Fortitude Kit

SARS-CoV-2 RT-PCR test for COVID-19

- First COVID-19 diagnostic test kit approved for use in Singapore through Provisional Authorization by Singapore's Health Sciences Authority(HSA).

- Deployed in 13 Singapore hospitals and labs and over 30 countries worldwide since February 2020. Exported to USA, Hong Kong, New Zealand, and Panama, among others.

- Can be combined with MiRXES Swab Collection System and MAGec automated RNA extraction solution for a complete end-to-end COVID-19 testing solution.

- Developed by researchers at Singapore's Agency for Science, Technology and Research (A*STAR) and Tan Tock Seng Hospital (TTSH). Technology has been licensed to MiRXES in February 2020 for mass production.

- MiRXES is a legal product owner of Fortitude Kit since March 2020.

Technical details

- A 1-step real-time RT-PCR test for detecting SARS-CoV-2 virus.

- Targets the portion of the virus genome that is less prone to mutation, enabling robust detection of the virus.

- Analytical Limit of Detection (LoD): 10 copies per reaction.

- Time from RNA to result: 90-120 minutes.

- Compatible with Bio-Rad, Applied Biosystems, and Roche real-time PCR equipment.

We deliver solutions

To patients

Patients can get our diagnostic tests at their family physician, specialist clinics, or health screening clinics.

To healthcare providers

We work with healthcare providers, including telehealth and insurtech, to deliver our early detection diagnostic tests to patients.

To clinical test labs

We work with clinical test labs to deliver molecular diagnostic test services to hospitals, clinics, and other healthcare providers.

The MiRXES advantage

World-leading technology, data, and capabilities

Our diagnostic solutions are powered by our unique class-leading qPCR technology platform, the world's largest clinical microRNA database, and our deep expertise in R&D and diagnostics manufacturing.

Early detection and dynamic prevention

microRNAs are more sensitive and specific disease biomarkers than traditional biomarkers.

microRNAs are stable in blood and more reliably detected in early stage disease compared to other biomarkers.

Non-invasive blood-based diagnostic solutions enable dynamic monitoring of disease risk with actionable results.

Explainer Video: microRNA biomarkers for disease detection

Play Video

No proprietary equipment required

Our qPCR-based solutions can be run in testing labs equipped with standard real-time PCR machines.